Combining SBRT and Lenalidomide for treating Solitary Plasmacytoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of combining Stereotactic Body Radiation Therapy (SBRT) with Lenalidomide in patients diagnosed with solitary plasmacytoma, a rare malignant plasma cell tumor. SBRT is a precision radiotherapy technique that delivers high doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues, potentially improving local control and reducing side effects. The trial aims to assess the local response rates and progression-free survival of patients receiving this combined treatment approach. Eligible participants must have newly diagnosed solitary plasmacytoma and meet specific diagnostic criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with newly diagnosed solitary plasmacytoma (SP).
* Age between 18 and 80 years.
* Diagnosis of SP must meet the following four criteria:

Biopsy-confirmed plasmacytoma in bone or soft tissue. No evidence of clonal plasma cell proliferation in the bone marrow. No other lesions detected on whole-body imaging (whole-body PET-CT or MRI recommended) except for the primary solitary lesion.

No end-organ damage caused by plasma cell disease, including SLiM CRAB \[excluding bone destruction caused by the SP itself.

Exclusion Criteria:

* Patients who are not suitable for radiotherapy or unable to receive SBRT due to technical limitations, such as patients with plasmacytoma in the extremities who cannot abduct the affected limb or maintain the treatment position due to pain.
* Eastern Cooperative Oncology Group (ECOG) performance status score greater than 2.
* Patients who meet the diagnostic criteria for multiple myeloma at the time of diagnosis: bone marrow biopsy showing more than 10% plasma cells, serum calcium level above 11.5 mg/dL, serum creatinine above 2 mg/dL, creatinine clearance rate below 40 mL/min, or hemoglobin below 10 g/dL.
* Patients with uncontrolled infectious comorbidities.
* Patients with other active malignancies.
* Pregnant or breastfeeding patients.
* Patients with a history or current pulmonary embolism.
* Patients with a history of autoimmune disease, even if it is controlled.
* Patients who are seropositive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) DNA \> 1,000 copies/mL.
* Patients with myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, or severe uncontrolled arrhythmia.
* Patients with neuropathy Grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events.
* Patients with neutrophil count \< 1×10\^9/L, hemoglobin \< 8 g/dL, or platelet count \< 75×10\^9/L.
* Patients with severely impaired liver or kidney function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 × upper limit of normal (ULN), total bilirubin \> 1.5 × ULN, or estimated glomerular filtration rate (eGFR) \< 40 mL/min.

Where it's running

• 2nd Affiliated Hospital, School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Ting Zhang, phD.
• Email: zezht@zju.edu.cn
• Phone: +86-571-87783521

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intelligent Video Laryngoscope to Help Emergency Intubations

  A smart video laryngoscope with AI is tested to help doctors place tubes in critically ill adults needing emergency intubation.

  Recruiting at 2 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT07922044

• Understanding anxiety, depression, and bipolar disorder over time in China

  This study tests how anxiety, depressive, and bipolar symptoms change over three years to find patterns that help with earlier recognition and prediction in people aged 12–55.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07903246

• Ultrasound-guided nasal bone fracture reduction

  This study tests whether using ultrasound to guide nasal bone fracture reduction can improve accuracy and outcomes for people with recent nasal injuries.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT07869563

• Simplified Tranexamic Acid Regimen for Trauma with Hemorrhage

  This trial tests a simplified TXA dosing approach to see if it safely helps adults with major trauma and significant bleeding.

  Recruiting at 3 sites Phase 4 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 2 other locations · NCT07869537

• Retrobulbar glucocorticoid injection for retinal light injury

  This study tests whether giving a retrobulbar glucocorticoid injection helps people who have retinal damage from bright light.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07869511

• Bevacizumab for severe HHT-related nosebleeds

  This study tests whether bevacizumab can help people with hereditary hemorrhagic telangiectasia who have severe nosebleeds.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07828015

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.